In addition, 5-HT1A (HTR1A) and 5-HT2A (HTR2A) have been identified as common targets for the treatment of insomnia, in both clinical and basic studies (Jiang et al., 2016; Ohno et al., 2018; Shao et al., 2020; Lv et al., 2021), as well as prevenient studies of ZSS for the treatment of insomnia (Shen et al., 2020). Here, HTR1A is linked to insomnia.